# DLBS1033 for Acute Ischemic Stroke Patients

> **NCT02133521** · PHASE2,PHASE3 · TERMINATED · sponsor: **Dexa Medica Group** · enrollment: 80 (actual)

## Conditions studied

- Acute Ischemic Stroke
- Partial Anterior Circulation Infarct
- Lacunar Anterior Circulation Infarct

## Interventions

- **DRUG:** DLBS1033
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02133521
- **Lead sponsor:** Dexa Medica Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-11-11
- **Primary completion:** 2023-02-21
- **Final completion:** 2023-04-21
- **Target enrollment:** 80 (ACTUAL)
- **Why stopped:** Very low recruitment rate. The Study Sites classified as tertiary referral hospital. Therefore, patients being referred to the site are mostly those with comorbidities included in the exclusion criteria.
- **Last updated:** 2023-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02133521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02133521, "DLBS1033 for Acute Ischemic Stroke Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02133521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*